Twist Bioscience Corporation
TWST
Κατάταξη σε μετοχές
#2144
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Τιμή μετοχής
$144.87
Κεφαλαιοποίηση
$9.54B
Αλλαγή (1 ημέρα)
3.65%
Αλλαγή (1 έτος)
342.47%
Χώρα
US
Εμπόριο Twist Bioscience Corporation (TWST)
Κατηγορία
Healthcare
Κέρδη για την Twist Bioscience Corporation (TWST)
Κέρδη τον Jun 2026 TTM: $-135.85M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Twist Bioscience Corporation, τα τρέχοντα κέρδη της εταιρείας είναι $-135.85M. Το 2024, η εταιρεία παρουσίασε κέρδη $-208.17M, μείωση σε σύγκριση με των κερδών του 2023 που ήταν $-203.47M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Twist Bioscience Corporation από 2016 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-135.85M | 76.55% |
| 2025 | $-76.95M | -63.03% |
| 2024 | $-208.17M | 2.31% |
| 2023 | $-203.47M | -10.87% |
| 2022 | $-228.27M | 48.20% |
| 2021 | $-154.03M | 10.38% |
| 2020 | $-139.55M | 29.96% |
| 2019 | $-107.38M | 51.25% |
| 2018 | $-70.99M | 20.27% |
| 2017 | $-59.03M | 33.89% |
| 2016 | $-44.09M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $7.61B | -5,700.87% |
US
|
|
| $4.76B | -3,605.23% |
US
|
|
| $-252.70M | 86.01% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,320.43% |
US
|
